A pocket-sized device that reads suspicious moles the way a specialist might has now been cleared by the U.S. Food and Drug Administration for use in ordinary primary-care offices. DermaSensor Inc., the Miami-based medical device company behind the tool, announced that its non-invasive skin-cancer evaluation system combines elastic scattering spectroscopy with a machine-learning algorithm trained to flag melanoma, basal cell carcinoma, and squamous cell carcinoma in seconds. It is the first FDA-authorized AI device of its kind aimed specifically at general practitioners rather than dermatologists.
How the Device Works
A clinician presses a small optical probe against a lesion, and the device shines light onto the skin and measures how it scatters off underlying tissue structures. An onboard algorithm compares that optical signature against a database built from tens of thousands of prior scans, producing a result in under three seconds. Because no biopsy or lab turnaround is required, primary-care doctors can use the readout during a routine visit to decide whether a referral to a dermatologist is warranted.
The Numbers Behind the Clearance
In the pivotal study supporting FDA clearance, the device demonstrated 96% sensitivity in detecting the three most common skin cancers, according to DermaSensor’s published clinical data. A negative reading carried a 97% likelihood of being genuinely benign, and researchers found that the rate of missed cancers among clinicians using the tool fell from 18% to 9% compared with unaided clinical judgment alone. Those figures come from studies that tracked how primary-care physicians’ diagnostic accuracy changed with and without the device’s input.
Why Primary Care Matters
Roughly one in five Americans will develop skin cancer in their lifetime, and most first present to a general practitioner rather than a dermatologist, according to dermatology research cited in coverage of the clearance. Wait times to see a dermatologist can stretch for weeks or months in many regions, and delayed detection of melanoma in particular can be the difference between a simple excision and a life-threatening diagnosis. Proponents argue that arming family doctors with an objective, standardized second opinion could catch cancers earlier and reduce unnecessary referrals for clearly benign spots.
Skeptics Point to Real-World Variability
Not every dermatologist is convinced the device is ready to reshape frontline care. Critics note that spectroscopy-based tools have historically produced more false positives in patients with darker skin tones or in lesions located on hard-to-scan areas like the scalp or between toes, and that the clinical trials underlying the clearance, while large, were conducted in controlled settings that may not fully reflect a busy walk-in clinic. Some dermatology groups have also raised concerns that overreliance on a rapid-fire device could erode referral patterns that currently ensure ambiguous cases reach a specialist’s trained eye rather than being waved off by a machine-generated “low risk” score.
What’s Next
The device is already sold in Europe and Australia and is priced on a subscription model, with U.S. pricing reported at $199 a month for up to five patients or $399 a month for unlimited use, according to company materials. With FDA clearance now in hand, DermaSensor is expected to pursue partnerships with primary-care networks and insurers to fold the device into standard visit workflows, while independent researchers continue to track its performance across diverse patient populations. If real-world data holds up, health-policy analysts say the clearance could become a template for how AI-assisted screening tools move from specialist offices into everyday checkups for other conditions. Insurers, too, are watching closely: whether payers agree to reimburse the device’s subscription cost will likely determine how quickly it spreads beyond early-adopter practices, since primary-care clinics operating on thin margins are unlikely to absorb a recurring software fee without a clear billing pathway. DermaSensor executives have said they are in discussions with several regional insurance networks about coverage pilots, and dermatology groups say they plan to publish their own post-market surveillance data within the next year to independently track how the device performs once it is in thousands of exam rooms rather than a handful of clinical-trial sites. Academic dermatology departments have also proposed joint registries that would pool anonymized scan results across health systems, an effort supporters say could answer lingering questions about performance across skin tones and body sites far faster than any single manufacturer-run study, while also giving the broader field independent data to weigh against DermaSensor’s own clinical claims.
